Tracon Pharmaceuticals, Inc. TCON
We take great care to ensure that the data presented and summarized in this overview for Tracon Pharmaceuticals, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in TCON
Top Purchases
Top Sells
About TCON
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Insider Transactions at TCON
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Oct 20
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+0.85%
|
$0
$0.13 P/Share
|
Apr 27
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
47,000
+10.53%
|
$0
$0.75 P/Share
|
Apr 26
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
3,999
+1.12%
|
$0
$0.66 P/Share
|
Apr 20
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+0.86%
|
$0
$0.14 P/Share
|
Apr 20
2023
|
Scott B. Brown CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,500
+12.23%
|
$0
$0.14 P/Share
|
Mar 09
2023
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
174,508
+3.88%
|
$174,508
$1.38 P/Share
|
Mar 01
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
4,800
+1.37%
|
$4,800
$1.52 P/Share
|
Feb 28
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
200
+0.06%
|
$200
$1.52 P/Share
|
Jan 18
2023
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
6,800
+1.96%
|
$6,800
$1.62 P/Share
|
Dec 29
2022
|
Scott B. Brown CHIEF FINANCIAL OFFICER |
BUY
Open market or private purchase
|
Direct |
3,500
+13.93%
|
$3,500
$1.49 P/Share
|
Dec 21
2022
|
William R Larue Director |
SELL
Open market or private sale
|
Direct |
120
-1.52%
|
$120
$1.26 P/Share
|
Dec 14
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
167,500
+4.57%
|
$167,500
$1.25 P/Share
|
Dec 14
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
23,000
+6.46%
|
$23,000
$1.29 P/Share
|
Dec 06
2022
|
Opaleye Management Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,539
-0.04%
|
$1,539
$1.44 P/Share
|
Dec 06
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
221,539
+5.23%
|
$0
$0.01 P/Share
|
Nov 18
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
13,900
+4.29%
|
$13,900
$1.41 P/Share
|
Nov 03
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
9,200
+3.01%
|
$9,200
$1.52 P/Share
|
Nov 02
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
6,000
+2.05%
|
$6,000
$1.59 P/Share
|
Oct 18
2022
|
Opaleye Management Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
12,500
+0.16%
|
$12,500
$1.65 P/Share
|
Oct 07
2022
|
Charles Theuer PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.77%
|
$5,000
$1.77 P/Share
|